Ozempic stock price saw a mild uptick in today’s pre-market trading, gaining 0.8% to $125.40 amid optimistic analyst revisions. Market sentiment leans bullish as upcoming quarterly earnings are expected to show stronger-than-forecast GLP-1 drug sales. Investors are tracking volume spikes as a potential sign of institutional accumulation. The bank dropped its rating to “ underweight ” from “equal weight,” and lowered the price target to $47 from $59. The stock was recently down less than 1% to below $55, slightly extending year-to-date declines. Shares of Novo Nordisk, the Danish drugmaker behind the popular diabetes and weight-loss drugs Ozempic and Wegovy, plummeted more than 20 percent on Tuesday after it said its sales this year would grow much less than previously expected. Ozempic stock price is on watch this week as several brokerages raise price targets to $130, citing stronger-than-expected Q3 prescription growth and expanding international market penetration. The consensus rating remains “Overweight” with projected annual EPS growth above sector average.
